Compare BANF & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANF | LGND |
|---|---|---|
| Founded | 1984 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.7B |
| IPO Year | 1994 | 1997 |
| Metric | BANF | LGND |
|---|---|---|
| Price | $112.89 | $285.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $124.00 | ★ $256.29 |
| AVG Volume (30 Days) | 86.6K | ★ 163.7K |
| Earning Date | 04-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | 10.40 | ★ 2886.36 |
| EPS | ★ 3.81 | 1.63 |
| Revenue | N/A | ★ $141,102,000.00 |
| Revenue This Year | $6.10 | $1.25 |
| Revenue Next Year | $3.92 | $19.41 |
| P/E Ratio | ★ $29.35 | $175.50 |
| Revenue Growth | N/A | ★ 29.48 |
| 52 Week Low | $101.48 | $161.82 |
| 52 Week High | $135.76 | $326.63 |
| Indicator | BANF | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 47.95 | 47.59 |
| Support Level | $111.03 | $179.99 |
| Resistance Level | $116.03 | $317.49 |
| Average True Range (ATR) | 2.10 | 8.50 |
| MACD | -0.20 | -0.08 |
| Stochastic Oscillator | 51.33 | 46.12 |
BancFirst Corp is engaged in providing banking services. The company's business unit includes BancFirst metropolitan banks, BancFirst community banks, Pegasus Bank, Worthington, other financial services and executive, operations and support. BancFirst metropolitan banks, BancFirst community banks, Pegasus and Worthington offer traditional banking products such as commercial and retail lending and a full line of deposit accounts. Its Other financial services are specialty product business units including guaranteed small business lending, residential mortgage lending, trust services, securities brokerage, electronic banking, and insurance.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.